Panacea Biotec

Panacea Biotec is a research-driven biotechnology company engaged in the research, development, manufacturing, and marketing of pharmaceuticals and vaccines. Founded in 1984 by Soshil Kumar Jain as Panacea Drugs Private Limited, the company was established with the goal of making specialized products affordable and accessible. Soshil Kumar Jain, a qualified pharmacist, began his career in the pharmaceutical industry in a chemist shop started by his father and had 56 years of experience in the sector. The company went public and was listed on Indian stock exchanges in September 1995, at which point its name was changed to Panacea Biotec Ltd.

The company's business model encompasses the entire value chain from research and development to sales and distribution. Revenue is primarily generated from two main segments: vaccines and pharmaceutical formulations, with the majority coming from the vaccines division. A significant portion of its revenue is derived from overseas markets. The company supplies its products to institutional customers such as UNICEF and PAHO, as well as marketing them in approximately 30 countries across the CIS, Latin America, the Middle East, Asia, and Africa. It operates state-of-the-art manufacturing facilities in locations like Baddi and Lalru, which are accredited by international bodies including the USFDA and WHO.

Panacea Biotec's product portfolio is extensive, covering therapeutic areas such as oncology, nephrology (organ transplantation), pain management, diabetes, and gastroenterology. A key achievement was the 2011 launch of PacliAll, the first generic version of the cancer drug Abraxane, which utilizes nanotechnology. The company holds a prominent position in the vaccine market, being a major manufacturer in India. It has been a significant partner in the Global Polio Eradication Initiative, supplying billions of doses of WHO pre-qualified polio vaccines globally. Notable products include EasyFive, the first fully-liquid pentavalent vaccine developed in 2005, and EasySix, the first fully-liquid hexavalent vaccine launched in 2017. The company has also been involved in developing vaccines for other diseases, including a collaboration with the Russian Direct Investment Fund to produce the Sputnik V COVID-19 vaccine.

Keywords: Panacea Biotec, biotechnology, pharmaceuticals, vaccine manufacturing, research and development, generic drugs, oncology, nephrology, organ transplant drugs, pain management, diabetes care, polio vaccines, pentavalent vaccine, hexavalent vaccine, Soshil Kumar Jain, EasyFive, EasySix, PacliAll, WHO prequalification, USFDA approved, pharmaceutical formulations, global drug distribution, nanotechnology in pharma, Indian pharmaceutical industry, Sputnik V production